US FDA OKs Korean neutropenia treatment drug

Hanmi Pharm said it has received approval from the U.S. Food and Drug Administration to conduct Phase 1 clinical trial of LAPS-GCSF (HM10460A, a drug for the treatment of neutropenia, following an approval on novel erythropoietin.

Lapscovery technology using Hanmi’s novel recombinant carrier exceeds the concept of pegylation or sustained-release formulation in maintaining the efficacy of bio...